Phase II Study of MK-3475 with and without Bevacizumab for Recurrent Glioblastoma

Investigator: Jennifer L. Clarke, MD, MPH

Location(s): United States


In this research study, the investigators are looking to determine the effectiveness of Pembrolizumab (MK-3475) when given with bevacizumab or when given alone for the treatment of recurrent glioblastoma multiforme (GBM). This study will also test the safety and tolerability of Pembrolizumab (MK-3475) when given alone or with bevacizumab.